How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aspirin-and-thienopyridine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Aspirin and thienopyridine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aspirin and thienopyridine (Aspirin and thienopyridine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual antiplatelet agent combination. Area: Cardiovascular.

marketed Dual antiplatelet agent combination COX-1 (aspirin); P2Y12 receptor (thienopyridine) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Aspirin and thienopyridine (Aspirin and thienopyridine) — Associations for Establishment of Evidence in Interventions. Aspirin and thienopyridine work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aspirin and thienopyridine TARGET	Aspirin and thienopyridine	Associations for Establishment of Evidence in Interventions	marketed	Dual antiplatelet agent combination	COX-1 (aspirin); P2Y12 receptor (thienopyridine)
Ticagrelor plus aspirin	Ticagrelor plus aspirin	Fujian Medical University	marketed	Dual antiplatelet agent combination	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual antiplatelet agent combination class)

Associations for Establishment of Evidence in Interventions · 1 drug in this class
Fujian Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aspirin and thienopyridine — Competitive Intelligence Brief. https://druglandscape.com/ci/aspirin-and-thienopyridine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab